Journal of Pharmaceutical Innovation

, Volume 10, Issue 2, pp 156–165 | Cite as

Product and Process Innovation in the Development Cycle of Biopharmaceuticals

Research Article
First Online:

Abstract

Purpose

The biopharmaceutical market has shown continuous growth under the intensive focus of the pharmaceutical industry. The processes for R&D and production of biopharmaceuticals are significantly more complex compared to those associated with small-molecule drugs. The complex structures of protein molecules make achieving successful development while meeting quality requirements challenging. We aimed to elucidate differences in patterns of product and process innovations between the biopharmaceutical and chemical-based pharmaceutical industries.

Methods

We tracked, categorized, and compared patented pharmaceutical and biopharmaceutical technologies along development cycles using International Patent Classification (IPC) codes.

Results

Our analyses illustrate patterns of product and process innovations in the biopharmaceutical industry and show how they differ from those of the chemical pharmaceutical industry.

Conclusions

Our study builds on the latest research on innovation theories to provide empirical evidence that demonstrates reshaping of innovation processes through utilization of scientific knowledge.

Keywords

Biopharmaceuticals Pharmaceuticals Process innovation Product innovation R&D process IPC code 
This is a preview of subscription content, log in to check access.

Supplementary material

12247_2015_9214_MOESM1_ESM.xlsx (269 kb)
ESM 1 (XLSX 269 kb)

References

  1. 1.
    Walsh G (2007) Pharmaceutical biotechnology: concepts and applications. 499Google Scholar
  2. 2.
    Walsh G. Biopharmaceuticals: biochemistry and biotechnology. 2nd ed. Chichester: Wiley; 2006.Google Scholar
  3. 3.
    Pisano G (1997) The development factory: unlocking the potential of process innovation.Google Scholar
  4. 4.
    Yi D (2008) Cancer, viruses, and mass migration: Paul Berg’s venture into eukaryotic biology and the advent of recombinant DNA research and technology, 1967–1980. J. Hist. BiolGoogle Scholar
  5. 5.
    PhRMA (2013) Medicine in development biologics 2013. 87.Google Scholar
  6. 6.
    EvaluatePharma (2014) World preview 2014, outlook to 2020Google Scholar
  7. 7.
    Sekhon, Bhupinder Singh; Saluja V (2011) Biosimilars: an overview. Biosimilars 1–11. doi: 10.2147/BS.S16120.Google Scholar
  8. 8.
    Rader R (2008) (Re) defining biopharmaceutical. Nat. Biotechnol.Google Scholar
  9. 9.
    Chen BB (2009) CMC issues and regulatory requirements for biosimilars. Trends Bio/Pharmaceutical Ind 19–26.Google Scholar
  10. 10.
    Närhi M, Nordström K (2005) Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective. Eur. J. Pharm.Google Scholar
  11. 11.
    Antosova Z, Mackova M, Kral V, Macek T. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol. 2009;27:628–35. doi: 10.1016/j.tibtech.2009.07.009.CrossRefPubMedGoogle Scholar
  12. 12.
    Broeze R (2006) Key challenges facing bio manufacturing. Bioprocess Biopartnering 1–3.Google Scholar
  13. 13.
    FDA (2004) Pharmaceutical CGMPs for the 21st century—a risk-based approach. Final report. Rockville, MD.Google Scholar
  14. 14.
    Cop PAT, Kourti T, Davis B. The business benefits of quality by design (QbD). Pharm Eng. 2012;32:1–10.Google Scholar
  15. 15.
    Lager T. A new conceptual model for the development of process technology in process industry. Int J Innov Manag. 2000;4:319–46.Google Scholar
  16. 16.
    Utterback JM. The dynamics of innovation. Educ Rev. 2004;43–51.Google Scholar
  17. 17.
    Utterback J (1996) Mastering the dynamics of innovation.Google Scholar
  18. 18.
    Juran JM (1992) Juran on quality by design: the new steps for planning quality into goods and services. 538.Google Scholar
  19. 19.
    Abu-Absi SF, Yang L, Thompson P, et al. Defining process design space for monoclonal antibody cell culture. Biotechnol Bioeng. 2010;106:894–905. doi: 10.1002/bit.22764.CrossRefPubMedGoogle Scholar
  20. 20.
    Lim LPL, Garnsey E, Gregory M. Product and process innovation in biopharmaceuticals: a new perspective on development. R&D Manag. 2006;36:27–36. doi: 10.1111/j.1467-9310.2006.00413.x.CrossRefGoogle Scholar
  21. 21.
    Lubiniecki A, Vargo S (1994) Regulatory practice for biopharmaceutical production.Google Scholar
  22. 22.
    Feldman M, Ronzio C (2001) Closing the innovative loop: moving from the laboratory to the shop floor in biotechnology manufacturing. Entrep. Reg.Google Scholar
  23. 23.
    Fall C, Törcsvári A, Benzineb K, Karetka G (2003) Automated categorization in the international patent classification. ACM SIGIR Forum.Google Scholar
  24. 24.
    Park H, Yoon J. Assessing coreness and intermediarity of technology sectors using patent co-classification analysis: the case of Korean national R&D. Scientometrics. 2013;98:853–90. doi: 10.1007/s11192-013-1109-2.CrossRefGoogle Scholar
  25. 25.
    Guan J, He Y. Patent-bibliometric analysis on the Chinese science-technology linkages. Scientometrics. 2007;72:403–25. doi: 10.1007/s11192-007-1741-1.CrossRefGoogle Scholar
  26. 26.
    Chen JH, Jang SL, Wen SH. Measuring technological diversification: identifying the effects of patent scale and patent scope. Scientometrics. 2010;84:265–75. doi: 10.1007/s11192-009-0143-6.CrossRefGoogle Scholar
  27. 27.
    Wang X, Zhang X, Xu S. Patent co-citation networks of fortune 500 companies. Scientometrics. 2011;88:761–70. doi: 10.1007/s11192-011-0414-x.CrossRefGoogle Scholar
  28. 28.
    Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9:203–14. doi: 10.1038/nrd3078.PubMedGoogle Scholar
  29. 29.
    Paulson D (2006) Handbook of regression and modeling. doi:  10.1201/9781420017380.
  30. 30.
    Behme S (2009) Manufacturing of pharmaceutical proteins: from technology to economy. Wiley.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Product Development DepartmentLG Life ScienceSeoulSouth Korea
  2. 2.Graduate School of Technology & Innovation ManagementHanyang UniversitySeoulSouth Korea

Personalised recommendations